title: Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.
authors.affiliation: Department of Pediatric Hematology and Oncology, Trousseau Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France Trousseau Hospital, Paris, France.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Héritier
authors.affiliation: Department of Pediatric Hematology and Oncology, Felix Guyon Hospital, Saint-Denis Réunion, France.
authors.forename: Mathilde
authors.initials: M
authors.lastname: Jehanne
authors.affiliation: Department of Pediatric Hematology and Oncology, Trousseau Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France Trousseau Hospital, Paris, France.
authors.forename: Guy
authors.initials: G
authors.lastname: Leverger
authors.affiliation: Pathology Department, Ambroise Paré Hospital, APHP, Boulogne, France.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Emile
authors.affiliation: Department of Pharmacology and Toxicology, Raymond Poincaré Hospital, APHP, Garches, France.
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Alvarez
authors.affiliation: Department of Internal Medicine & French Reference Center for Rare Auto-immune & Systemic Diseases, Pitié-Salpêtrière Hospital, APHP, Paris, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Haroche
authors.affiliation: Department of Pediatric Hematology and Oncology, Trousseau Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France Trousseau Hospital, Paris, France.
authors.forename: Jean
authors.initials: J
authors.lastname: Donadieu
mesh_terms: D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D005260:Female; D020022:Genetic Predisposition to Disease; D006646:Histiocytosis, Langerhans-Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D006801:Humans; D007211:Indoles / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007223:Infant; D058990:Molecular Targeted Therapy; D009154:Mutation; D010641:Phenotype; D047428:Protein Kinase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D012074:Remission Induction; D013449:Sulfonamides / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D000077484:Vemurafenib
chemical_list: D014408:Biomarkers, Tumor; D007211:Indoles; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf